MedTrace Logo

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

NCT05578053 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 420

Last updated 2025-09-11

No results posted yet for this study

Summary

This study is a multi-center, observational, real-world study. We planned to recruit 420 HR+ locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy. All patients included in the analysis were receiving or planning to receive dalpiciclib-containing regimens without restrictions, completely following the physician 's clinical choice, to assess the efficacy and safety of dalpiciclib-containing regimens.

Conditions

Interventions

DRUG

Dalpiciclib

a new, orally administered, selective CDK4/6 inhibitor

Sponsors & Collaborators

  • Hebei Medical University Fourth Hospital

    lead OTHER

Principal Investigators

  • Cuizhi Geng Cuizhi Geng, archiater · Hebei Medical University Fourth Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-13
Primary Completion
2028-12-01
Completion
2030-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05578053 on ClinicalTrials.gov